NEW YORK--(EON: Enhanced Online News)--Only 2 percent of ongoing type 1 diabetes clinical trials in 2013 have the potential to deliver a cure in the next decade, according to the Juvenile Diabetes Cure Alliance’s annual State of the Cure report.
“The small number of near-term projects, coupled with the demands of donors, underscores the need to increase funding for near-term cure research. Donors deserve assurance that their intentions match project potential and that donations are an investment, not a gamble.”
Released today, the report analyzed the more than 300 type 1 diabetes research projects in human clinical trials as well as donor attitudes, funding realities and operational practices for the four major diabetes nonprofits. Of the type 1 diabetes projects in clinical trials today, only six would impact the current generation of people with type 1 diabetes if brought to market. Beyond the six clinical trials outlined in the report, the JDCA identified three pre-clinical trial projects, including a bio-engineered mini-organ and cell transplantation project, that could be on the path to delivering a near term cure.
“Only a handful of research projects are working toward a near-term cure,” said Aaron Gorin, director of research for the JDCA. “In order to increase the chances of making a meaningful change for people now living with the disease, more of these types of projects need to progress to human trials. Funding and resourcing should not be what holds these projects back when they are exactly what people with type 1 diabetes and their families want and give money to support.”
While the American Diabetes Association, JDRF, Joslin Diabetes Center and Diabetes Research Institute Foundation received $398 million in donations in 2012, only 2 percent went toward promising cure projects like cell retraining and islet transplantation. This is in direct contrast to the wishes of people with type 1 diabetes and their families. A survey conducted by the JDCA earlier this year found that nine of out of 10 diabetes donors prefer that research funds support a near-term practical cure rather than a long-term, total cure.
The number of cure projects favored by donors remains unchanged from 2012, and human clinical trials either are ongoing or on hold based on lack of funds. Because of donor expectations and the number of existing projects, the JDCA is calling for the four major diabetes nonprofits to direct at least 25 percent of donor contributions to a near-term cure.
“There have been encouraging developments in 2013, but the nonprofits and researchers need to implement a mechanism for prioritizing projects that fully funds and resources the most promising near-term projects,” said Phil Shaw, general manager of the JDCA. “The small number of near-term projects, coupled with the demands of donors, underscores the need to increase funding for near-term cure research. Donors deserve assurance that their intentions match project potential and that donations are an investment, not a gamble.”
The full State of the Cure Report can be downloaded on the JDCA’s reports page.
About the JDCA
The JDCA is an independent analyst of the type 1 diabetes charitable universe and brings a business-like perspective to help donors focus research toward a practical cure. The mission of the JDCA is to achieve a type 1 practical cure before 2025 by steering donor contributions to the most effective charities.
Become an Alliance member: http://bit.ly/JointheJDCA
Become a fan on Facebook: https://www.facebook.com/thejdca
Follow us on Twitter: https://twitter.com/JDCA2025